Abstract
The etiopathogenesis of severe COVID-19 remains unknown. Indeed given major confounding factors (age and co-morbidities), true drivers of this condition have remained elusive. Here, we employ an unprecedented multi-omics analysis, combined with artificial intelligence, in a young patient cohort where major co-morbidities have been excluded at the onset. Here, we established a three-tier cohort of individuals younger than 50 years without major comorbidities. These included 47 “critical” (in the ICU under mechanical ventilation) and 25 “non-critical” (in a noncritical care ward) COVID-19 patients as well as 22 healthy individuals. The analyses included whole-genome sequencing, whole-blood RNA sequencing, plasma and blood mononuclear cells proteomics, cytokine profiling and high-throughput immunophenotyping. An ensemble of machine learning, deep learning, quantum annealing and structural causal modeling led to key findings. Critical patients were characterized by exacerbated inflammation, perturbed lymphoid/myeloid compartments, coagulation and viral cell biology. Within a unique gene signature that differentiated critical from noncritical patients, several driver genes promoted severe COVID-19 among which the upregulated metalloprotease ADAM9 was key. This gene signature was replicated in an independent cohort of 81 critical and 73 recovered COVID-19 patients, as were ADAM9 transcripts, soluble form and proteolytic activity. Ex vivo ADAM9 inhibition affected SARS-CoV-2 uptake and replication in human lung epithelial cells. In conclusion, within a young, otherwise healthy, COVID-19 cohort, we provide the landscape of biological perturbations in vivo where a unique gene signature differentiated critical from non-critical patients. The key driver, ADAM9, interfered with SARS-CoV-2 biology. A repositioning strategy for anti-ADAM9 therapeutic is feasible.
One sentence summary Etiopathogenesis of severe COVID19 in a young patient population devoid of comorbidities.
Competing Interest Statement
RL, RG, SG, JL, HW, JRG and TWC are employees of Genuity Science. TWC, RC and SB, are, thru their employers, named as inventors on two patent applications covering findings reported in this work. The remaining authors have no conflicts of interest to declare.
Funding Statement
This work was supported by the Strasbourg Interdisciplinary Thematic Institute (ITI) for Precision Medicine, TRANSPLANTEX NG, as part of the ITI 2021-2028 program of the University of Strasbourg, CNRS and INSERM, funded by IdEx Unistra (ANR-10-IDEX-0002 to S. Bahram) and SFRI-STRATUS (ANR-20-SFRI-0012 to S. Bahram); Institut National de la Sante et de la Recherche Medicale UMR_S 1109, the Institut Universitaire de France, and MSD-Avenir grant AUTOGEN (all to S. Bahram); the University of Strasbourg (including Initiative d'Excellence IDEX UNISTRA; to S. Bahram and R. Carapito); the European Regional Development Fund (European Union) INTERREG V program PERSONALIS (to R. Carapito and S. Bahram); the French Proteomic Infrastructure (ProFI; ANR-10-INBS-08-03; to C. Carapito); France Medecine Genomique 2025 (to D. Sanlaville); and Genuity Science. This work was partially supported by a DOE/HEP QuantISED program grant, QCCFP/Quantum Machine Learning and Quantum Computation Frameworks (QCCFP-QMLQCF) for HEP (Grant No. DE-SC0019219 to DAL).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethics committee of Strasbourg University Hospitals approved the study (COVID-HUS, reference CE: 2020-34). Written informed consent was obtained from all the patients.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.
